nach oben

Die Diabetologie

Erschienen in:

23.08.2017 | Koronare Herzerkrankung | Leitthema

Therapie postprandialer Blutzuckerspitzen – sinnvoll oder nur Blutzuckerkosmetik?

Pro

verfasst von: Prof. Dr. T. Forst

Erschienen in: Die Diabetologie | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Diabetes mellitus Typ 2 ist eine komplexe Erkrankung, die mit einem erhöhten Risiko für mikro- und makrovaskuläre Erkrankungen verknüpft ist. Die Bedeutung einer verbesserten metabolischen Kontrolle und insbesondere postprandialer Blutzuckerexkursionen wird hierbei kontrovers diskutiert.

Datenlage

Während die Resultate der Mehrzahl der epidemiologischen Untersuchungen auf einen Zusammenhang zwischen postprandialen Blutzuckerspitzen und dem Auftreten vaskulärer Komplikationen bei Personen mit und ohne Diabetes hinweisen, erscheint die Datenlage aus prospektiven, randomisierten klinischen Studien unklar. In zahlreichen mechanistischen Arbeiten konnte eine Verbindung zwischen akuten Blutzuckerspitzen und der Aktivierung vasopathogener Signalkaskaden dargestellt werden.

Resümee

Ziel dieses Beitrags ist, einen Überblick über die derzeit verfügbare Evidenz zur Bedeutung der Einstellung des postprandialen Blutzuckerspiegels für eine Risikoreduktion vaskulärer Komplikationen bei Patienten mit Diabetes mellitus Typ 2 zu geben.

Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393CrossRefPubMed

Gerstein HC, Miller ME, Genuth S et al (2011) Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364:818–828CrossRefPubMed

Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRefPubMed

Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139CrossRefPubMed

Succurro E, Marini MA, Arturi F et al (2009) Elevated one-hour post-load plasma glucose levels identifies subjects with normal glucose tolerance but early carotid atherosclerosis. Atherosclerosis 207:245–249CrossRefPubMed

Marini MA, Succurro E, Castaldo E et al (2012) Cardiometabolic risk profiles and carotid atherosclerosis in individuals with prediabetes identified by fasting glucose, postchallenge glucose, and hemoglobin A1c criteria. Diabetes Care 35:1144–1149CrossRefPubMedPubMedCentral

Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M (2000) Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 23:1830–1834CrossRefPubMed

Sciacqua A, Maio R, Miceli S et al (2012) Association between one-hour post-load plasma glucose levels and vascular stiffness in essential hypertension. PLOS ONE 7(9):e44470CrossRefPubMedPubMedCentral

Gordin D, Ronnback M, Forsblom C, Heikkila O, Saraheimo M, Groop PH (2007) Acute hyperglycaemia rapidly increases arterial stiffness in young patients with type 1 diabetes. Int J Obes Relat Metab Disord 50:1808–1814

10.

Kawano H, Motoyama T, Hirashima O et al (1999) Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 34:146–154CrossRefPubMed

11.

Sciacqua A, Miceli S, Carullo G et al (2011) One-hour postload plasma glucose levels and left ventricular mass in hypertensive patients. Diabetes Care 34:1406–1411CrossRefPubMedPubMedCentral

12.

Kuroda M, Shinke T, Sakaguchi K et al (2015) Association between daily glucose fluctuation and coronary plaque properties in patients receiving adequate lipid-lowering therapy assessed by continuous glucose monitoring and optical coherence tomography. Cardiovasc Diabetol 14:78CrossRefPubMedPubMedCentral

13.

Kataoka Y, Yasuda S, Morii I, Otsuka Y, Kawamura A, Miyazaki S (2005) Quantitative coronary angiographic studies of patients with angina pectoris and impaired glucose tolerance. Diabetes Care 28:2217–2222CrossRefPubMed

14.

Coutinho M, Gerstein HC, Wang Y, Yusuf S (1999) The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22:233–240CrossRefPubMed

15.

DECODE Study Group (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2‑hour diagnostic criteria. Arch Intern Med 161:397–405CrossRef

16.

Metter EJ, Windham BG, Maggio M et al (2008) Glucose and insulin measurements from the oral glucose tolerance test and mortality prediction. Diabetes Care 31:1026–1030CrossRefPubMedPubMedCentral

17.

Bergman M, Chetrit A, Roth J, Dankner R (2016) One-hour post-load plasma glucose level during the OGTT predicts mortality: observations from the Israel Study of Glucose Intolerance, Obesity and Hypertension. Diabet Med 33(8):1060–1066. https://doi.org/10.1111/dme.13116 CrossRefPubMed

18.

Di AE, Gao P, Khan H et al (2014) Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA 311:1225–1233CrossRef

19.

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486–494CrossRefPubMed

20.

Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T (2004) Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 35:1073–1078CrossRefPubMed

21.

Holman RR, Haffner SM, McMurray JJ et al (2010) Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1463–1476CrossRefPubMed

22.

Raz I, Wilson PW, Strojek K et al (2009) Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 32:381–386CrossRefPubMedPubMedCentral

23.

Raz I, Ceriello A, Wilson PW et al (2011) Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia. Diabetes Care 34:1511–1513CrossRefPubMedPubMedCentral

24.

Nappo F, Esposito K, Cioffi M et al (2002) Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol 39:1145–1150CrossRefPubMed

25.

Ceriello A (1993) Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Int J Obes Relat Metab Disord 36:1119–1125

26.

Marfella R, Nappo F, De AL, Siniscalchi M, Rossi F, Giugliano D (2000) The effect of acute hyperglycaemia on QTc duration in healthy man. Int J Obes Relat Metab Disord 43:571–575

27.

Forst T, Kunt T, Kazda C, Lobisch M, Pfützner A (2002) Die Rolle der Proteinkinase C in der Entwicklung mikrovaskulärer Komplikationen des Diabetes mellitus. Diabetes Stoffwechs 11:62–70

28.

Forst T, Kunt T, Pohlmann T et al (1998) Microvascular skin blood flow following the ingestion of 75g Glucose in healthy individuals. Exp Clin Endocrinol Diabetes 106:453–458

29.

Scognamiglio R, Negut C, De Kreutzenberg SV, Tiengo A, Avogaro A (2005) Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation 112:179–184CrossRefPubMed

30.

Scognamiglio R, Negut C, De Kreutzenberg SV, Tiengo A, Avogaro A (2006) Effects of different insulin regimes on postprandial myocardial perfusion defects in type 2 diabetic patients. Diabetes Care 29:95–100CrossRefPubMed

31.

Forst T, Forst S, Strunk K et al (2005) Impact of insulin on microvascular blood flow and endothelial cell function in the postprandial state in patients with Type 1 diabetes. J Diabetes Complicat 19:128–132CrossRefPubMed

32.

Ceriello A, Cavarape A, Martinelli L et al (2004) The post-prandial state in Type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med 21:171–175CrossRefPubMed

33.

Forst T, Pfutzner A, Flacke F et al (2010) Postprandial vascular effects of VIAject compared with insulin lispro and regular human insulin in patients with type 2 diabetes. Diabetes Care 33:116–120CrossRefPubMed

34.

Pyorala K, Savolainen E, Lehtovirta E, Punsar S, Siltanen P (1979) Glucose tolerance and coronary heart disease: Helsinki policemen study. J Chronic Dis 32:729–745CrossRefPubMed

35.

Donahue RP, Abbott RD, Reed DM, Yano K (1987) Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 36:689–692CrossRefPubMed

36.

Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J (1997) Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 20:163–169CrossRefPubMed

37.

Balkau B, Shipley M, Jarrett RJ et al (1998) High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 21:360–367 (see comments)CrossRefPubMed

38.

Jackson CA, Yudkin JS, Forrest RD (1992) A comparison of the relationships of the glucose tolerance test and the glycated haemoglobin assay with diabetic vascular disease in the community. The Islington Diabetes Survey. Diabetes Res Clin Pract 17:111–123CrossRefPubMed

39.

de Vegt F, Dekker JM, Ruhe HG et al (1999) Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Int J Obes Relat Metab Disord 42:926–931

40.

Barrett-Connor E, Ferrara A (1998) Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 21:1236–1239CrossRefPubMed

41.

Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ (1999) Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Int J Obes Relat Metab Disord 42:1050–1054

42.

Hanefeld M, Fischer S, Julius S et al (1996) Risk factors for myocardial ifarction and death in newly detected NIDDM: the diabetes intervention study, 11 year follow up. Diabetologia 39:1577–1583CrossRefPubMed

43.

Meigs JB, Nathan DM, D’Agostino RB Sr., Wilson PW (2002) Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 25:1845–1850CrossRefPubMed

44.

Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A (1999) Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care 22:920–924CrossRefPubMed

45.

Barzilay JI, Spiekerman CF, Wahl PW et al (1999) Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet 354:622–625CrossRefPubMed

46.

Saydah SH, Loria CM, Eberhardt MS, Brancati FL (2001) Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care 24:447–453CrossRefPubMed

Titel: Therapie postprandialer Blutzuckerspitzen – sinnvoll oder nur Blutzuckerkosmetik?
Pro
verfasst von: Prof. Dr. T. Forst
Publikationsdatum: 23.08.2017
Verlag: Springer Medizin
Schlagwörter: Koronare Herzerkrankung
Arteriosklerose
Typ-2-Diabetes
Diabetes mellitus
Glukosebelastungstest
Erschienen in: Die Diabetologie / Ausgabe 6/2017
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI: https://doi.org/10.1007/s11428-017-0259-x

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.

Zu den Praxisempfehlungen

Springer Medizin

Zusammenfassung

Hintergrund

Datenlage

Resümee

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2017

Inzidenz der diabetischen Nephropathie

Verzichtbar: Formuladiäten zum Abnehmen bei Typ-2-Diabetes

Sinnvoll: Formuladiäten zum Abnehmen bei Typ-2-Diabetes

Magazin

Gibt es die richtige Ernährung für "gesundes Altern"?

Therapie postprandialer Blutzuckerspitzen – sinnvoll oder nur Blutzuckerkosmetik?

Praxisempfehlungen der Deutschen Diabetes Gesellschaft